Skip to content
OpenCapital
Get started

Johnson & Johnson JNJ Innovative Medicine — Other (income) expense, net

Other segment segments

MEDTECH
$76M+227%

Similar metrics at other companies

DXP Enterprises logo
DXPEInnovative Pumping Solutions — Other Nonoperating Income (Expense)
$0—
Asset Entities logo
ASSTMedical Device — Other Operating Income
$0—
Becton, Dickinson and Company logo
BDXMedical — Other Operating Income
$4.25M+950%
Amneal Pharmaceuticals, Inc. logo
AMRXAffordable Medicines — Other Operating Income
$6.94M+35.5%
MoonLake Immunotherapeutics logo
MLTXOther Nonoperating Income
$3.21M-54.8%
Bruker logo
BRKROther Income (Expense)
$11.7M+275%

Other financials

Income statement

See full
Revenue$24.1B+9.9%
Gross profit$16.0B+9.8%
Operating income$6.3B+2.3%
Net income$5.2B-52.4%
EPS (diluted)$2.14-52.9%

Balance sheet

See full
Cash & equivalents$21.7B-43.6%
Total debt$55.0B+5.2%
Total equity$81.2B+3.9%
Total assets$200.89B+3.7%

Cash flow

See full
Operating cash flow$2.5B-39.8%
CapEx$1.0B+31.9%
Free cash flow$1.5B-56.6%

Valuation

See full
Market cap$623.71B+66.9%
Enterprise value$657.01B+61.9%
P/E29.6×+13.2×
P/S6.5×+2.3×

Profitability

See full
Gross margin67.8%-0.5pp
Operating margin26.4%+2.8pp
Net margin21.8%-2.6pp
FCF margin18.5%-4.3pp

Returns & leverage

See full
Return on equity26.4%-3.0pp
Debt / equity0.7×0.0×
Current ratio1×-0.2×

Where this comes from

Reported directly by Johnson & Johnson in its filing.

Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.

The official record: Johnson & Johnson’s 10-Q, filed April 22, 2026, on SEC EDGAR. View the filing →

Ask your AI about Johnson & Johnson's innovative medicine — other (income) expense, net.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Johnson & Johnson's innovative medicine — other (income) expense, net?
Johnson & Johnson (JNJ) reported innovative medicine — other (income) expense, net of -$12M in Q1 2026.
How has Johnson & Johnson's innovative medicine — other (income) expense, net changed year-over-year?
Johnson & Johnson's innovative medicine — other (income) expense, net increased by 92.8% year-over-year, from -$166M to -$12M.
What is the long-term trend for Johnson & Johnson's innovative medicine — other (income) expense, net?
Over 3 years (2022 to 2025), Johnson & Johnson's innovative medicine — other (income) expense, net has grown at a -21.9% compound annual growth rate (CAGR), from $1.49B to -$713M.
What does innovative medicine — other (income) expense, net mean?
Includes non-operating items such as interest income, gains or losses on asset sales, and other miscellaneous financial impacts specific to the Innovative Medicine segment. This metric captures secondary financial activities that are not part of core manufacturing or sales operations. It provides a more complete picture of the segment's total financial contribution.